Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil vs Ruxolitinib for Hepatic cGVHD
NCT07794514Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Randomised, open-label trial of belumosudil and ruxolitinib in hepatic chronic graft-versus-host disease (4 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall Response Rate at 24 weeks. Started Oct 2026; status: recruiting.
02
Drugs
belumosudilruxolitinib
03
Conditions
hepatic chronic graft-versus-host disease
Beyond the preview
Go deeper on NCT07794514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794514.